Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…

Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Surgical washout and antimicrobial principles

Musculoskeletal medicine and orthopaedics · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Source control and sepsis treatment proceed together

Pus, necrotic tissue, infected implants and closed-space pressure remain biologically active despite antibiotics; delayed or incomplete washout permits cartilage loss, bacteraemia, tissue death and repeated operations.

Action: Resuscitate and culture without harmful delay, start intravenous treatment immediately in sepsis, mobilise the appropriate surgical and anaesthetic team, expose every involved compartment, obtain multiple separately instrumented deep samples before irrigation, excise non-viable tissue, drain thoroughly and define the re-look and antibiotic review before leaving theatre.

Synopsis

Understand washout as structured source control rather than irrigation alone, preserve deep microbiology, match surgical access to anatomy, and connect empirical, directed and follow-up antimicrobial decisions to operative findings.

  • Washout is a source-control package: adequate exposure, decompression, drainage, excision of non-viable tissue, representative sampling, dead-space management and a documented closure or re-look plan.
  • Stable patients should provide blood and deep samples before antibiotics. Septic patients receive intravenous treatment after rapidly obtainable blood cultures even if theatre or aspiration is delayed.
  • Take fluid before irrigation and multiple deep tissue samples with a fresh sterile instrument for each; five microbiology specimens are the BOASt standard for fracture-related and peri-prosthetic infection.
  • Choose arthroscopic, open or image-guided access from joint, loculation, tissue state, implants, surgeon expertise and the need to debride bone or exchange components.
  • Do not call a small incision and irrigation definitive when necrotic fascia, sequestrum, infected non-union or mature implant biofilm remains outside the field.
  • Start empirical broad treatment after samples, review at 48 hours with preliminary culture results and narrow to organism, allergies, renal function, surgical strategy and local resistance.
  • Failure to improve prompts repeat examination, culture review and imaging and often repeat washout; simply extending or broadening antibiotics does not sterilise retained pus or avascular tissue.
  • Document postoperative weight-bearing, wound and drain plan, thrombosis prevention, analgesia, rehabilitation, laboratory monitoring and the named team responsible for culture follow-up.

Key red flags

Shock, rising lactate, altered consciousness or progressive organ dysfunction requires immediate sepsis antibiotics and emergency source control rather than prolonged diagnostic optimisation.

Necrotising features, compartment pressure, neurovascular compromise, rapidly spreading tissue change or gas demand radical exploration beyond a limited washout.

Persistent fever, pain, CRP rise, positive blood cultures or ongoing drainage after surgery indicates inadequate source control, another focus or ineffective therapy until investigated.

A prosthesis, fracture fixation, unstable bone, poor perfusion or major soft-tissue defect changes the operation and requires implant, vascular and reconstructive expertise rather than isolated lavage.

Investigation priorities

01
Preoperative blood culturesFirst step

Identify systemic organisms before antibiotics when rapidly possible.

Management branches

EmergencyResuscitate and operate

Sepsis, necrotising infection, neurovascular threat or rapidly destructive closed-space infection is present.

  1. Take rapid blood cultures, start intravenous therapy and mobilise theatre and critical care concurrently.
  2. Expose the entire threatened anatomy, obtain deep samples and drain or excise all non-viable infected tissue.
  3. Restore perfusion, decompress compartments and stabilise unsafe bone with relevant specialist teams.
  4. Leave a documented re-look threshold and treat deterioration as incomplete source control.
PlannedProtect microbiology and reconstruction

The patient is stable and a deep infection operation can be deliberately designed.

  1. Withhold empirical antibiotics, review imaging, implants, union, perfusion and soft-tissue cover and agree the surgical endpoint.
  2. Take pre-irrigation fluid, five separate deep cultures and indicated histology before antimicrobials.
  3. Debride to viable tissue, manage dead space, implant stability and coverage and document any retained risk.
  4. Start empirical therapy after samples and review at 48 hours with preliminary culture results.

Key medicines

Empirical treatment after operative samplingImmediately after pre-irrigation fluid and deep tissue specimens are secured, give the complete adult agent, route, dose and interval from the trust's anatomical infection protocol; review at 48 hours against preliminary cultures and the operation performed.Account for allergy, renal and liver function, previous isolates, healthcare exposure and local resistance; do not conceal poor source control with escalating breadth, and record exact timing relative to samples.
Organism-directed continuationPrescribe the narrowest active regimen with exact route, frequency, monitoring and stop or review date agreed by infection specialists, using a reliable oral agent when appropriate and linking duration to retained implants, bone involvement, drainage and response.Review absorption, pregnancy, renal and hepatic adjustment, marrow toxicity, QT risk and drug interactions; biofilm-active combinations require specific indication and must not be used as unsupported monotherapy.
Open full textbook →Answer 2 questions
Sources and review status5 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • BOASt - Fracture Related Infections
  • BOASt - Acute Management of Peri-Prosthetic Joint Infection
  • BOASt - Management of musculoskeletal soft tissue infections
  • Guideline for management of septic arthritis in native joints
  • NICE NG15 Antimicrobial stewardship

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom